US Geriatric Assessment Practices for Older Adults Undergoing Hematopo... https://t.co/ocZ7uumqC9
In a first of its kind team effort with a so grateful for the commitment and mentorship by all! @MediHumdani,Andy Artz, Paul Carpenter @ASTCT improving our survey methodologies🤞🏼
New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use. https://t.co/hk4tBDeQAX
I'm concerned that the recent @statnews piece re: decline of #BMT by @angRchen could be misleading to the public. Adding some context for consideration in the thread 🧵below: https://t.co/A2VBjwyWiB
2024's top 10 advances in biology (🧵)
1. Progress in longevity
Blocking the pro-inflammatory cytokine, IL11, extended healthspan and lifespan (in mice!)
Old mice without IL11 look healthier, they're stronger, and they live longer
https://t.co/Y0Raog12xk
Fascinating new study shows that patients with chronic pain who are cared for by more empathic physicians have better outcomes, not just in pain scores but also function and quality of life. #hapc#pallonc https://t.co/AX2yL4Pz0u
@Karthik_Nath17 giving a fine presentation on our work comparing older siblings to younger matched URDs when PTCy is used. Younger URDs improved disease free survival compared to older siblings. Manuscript coming!
We reported the longest follow up of using BsAbs in lymphoma. With a median 3.5 years f/u, the DOCR for patients treated with mosunetuzumab is not reached. No relapses post 26 months. Retreatment worked in 10/12 including 7 CRs.
https://t.co/TRnSrwzNVa
Weekend review 📖
What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days?
Brief review of literature in this 🧵
#leusm#AML
Our multisite RCT of integrated specialist #palliativecare in 360 pts undergoing stem cell transplantation demonstrates the superiority of this care model. Very proud to be part of this practice changing study, led by @Areejmd, w/ @JasAWebb and @StephanieLeeMD#ash23#hapc
If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR@mshadman Reminds you to keep an open mind,
one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23
Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With #Cancer: Economic Evaluation Within 5C Trial | Journal of Clinical Oncology @JCO_ASCO #gerionc#geriheme https://t.co/Bt0xEQy3vA